CoChat

Lithium: the pharmacodynamic actions of the amazing ion

Open access
Brown, Kayleigh M., Tracy, Derek K. · 2013 · Therapeutic Advances in Psychopharmacology

The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.

Abstract

Lithium has been used for the treatment of mood disorders for over 60 years, yet the exact mechanisms by which it exerts its therapeutic effects remain unclear. Two enzymatic chains or pathways emerge as targets for lithium: inositol monophosphatase within the phosphatidylinositol signalling pathway and the protein kinase glycogen synthase kinase 3. Lithium inhibits these enzymes through displacing the normal cofactor magnesium, a vital regulator of numerous signalling pathways. Here we provide an overview of evidence, supporting a role for the inhibition of glycogen synthase kinase 3 and inositol monophosphatase in the pharmacodynamic actions of lithium. We also explore how inhibition of these enzymes by lithium can lead to downstream effects of clinical relevance, both for mood disorders and neurodegenerative diseases. Establishing a better understanding of lithium’s mechanisms of action may allow the development of more effective and more tolerable pharmacological agents for the treatment of a range of mental illnesses, and provide clearer insight into the pathophysiology of such disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2045125312471963

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 124 references

Research works printed but not linked: 7

  1. Bowden C., 2000, J Clin Psychiatry, 61, 35
  2. Burgess S., 2001, Cochrane Database Syst Rev, CD003013
  3. Coppen A., 2000, J Clin Psychiatry, 61, 52
  4. Lenox R., 2000, J Clin Psychiatry, 61, 5
  5. Li J., 2012, Plos One, 7, 8
  6. Manji H., 2000, J Clin Psychiatry, 61, 82
  7. Tondo L., 2000, J Clin Psychiatry, 61, 97

Cited by

See all 146

Metadata

Authors
Brown, K. M., & Tracy, D. K.
Affiliations
  • King's College London (GB)
  • Oxleas NHS Foundation Trust (GB)
Venue
Therapeutic Advances in Psychopharmacology
Published
2012-12-21
Volume
3
Issue
3
Pages
163-176
ISSN
  • 2045-1253 (ISSN-L)
  • 2045-1261
OpenAlex
W2131991500
Cited by
140
References
124
Citations by year
2026: 13 · 2025: 18 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 8 · 2020: 9 · 2019: 10 · 2018: 10 · 2017: 9 · 2016: 9 · 2015: 18 · 2014: 8 · 2013: 1
FWCI
6.15
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Therapeutic Advances in Psychopharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion, other-oa)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
lithium, pharmacodynamics, glycogen synthase kinase-3, inositol monophosphatase, magnesium cofactor, mood disorders, neurodegenerative diseases, enzyme inhibition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lithium: the pharmacodynamic actions of the amazing ion. https://app.cochat.ai/papers/10.1177/2045125312471963
The paper
Brown, K. M., & Tracy, D. K. (2013). Lithium: the pharmacodynamic actions of the amazing ion. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125312471963

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.